Curevo Vaccine has announced an upcoming oral presentation at the World Vaccine Congress regarding the positive outcomes data from its Phase 2 trial of amezosvatein, with zero shingles cases reported among participants after 18.8 months.
Company Information
Company
Curevo
Location
Bothell, Washington, United States
About
Curevo is a clinical-stage biotechnology company dedicated to developing vaccines with improved tolerability and accessibility. Its lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to prevent shingles, a serious medical condition involving a painful, blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Curevo ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.